Literature DB >> 17156696

Clinical characteristics and prognostic factors of postencephalitic epilepsy in children.

Yung-Jung Chen1, Peng-Cheng Fang, Julie Chiu Chow.   

Abstract

The goal of this study was to clarify the clinical characteristics and prognostic factors of childhood postencephalitic epilepsy. Forty-four patients (20 boys and 24 girls; age range 21 months to 17 years, mean age 8.1 +/- 4.6 years) with postencephalitic epilepsy were selected from the 798 epileptic children treated and followed up at our hospital between 1993 and 2003. The clinical data included clinical features, electroencephalograms (EEGs), and neuroimages, all reviewed and analyzed retrospectively. Based on their post-treatment seizure outcomes, the children were divided into favorable (n = 20) and poor outcome groups (n = 24). Between the two groups, the age at encephalitis, cerebrospinal fluid findings, and seizure type were comparable. Factors indicating a poor prognosis for these patients during the acute phase of encephalitis were (1) status epilepticus occurring as the first seizure (P < .005), (2) slow background activity (P < .001) and multifocal spike discharges on EEGs (P < .01), and (3) herpes simplex viral encephalitis (P < .01). Our findings indicated that patients with status epilepticus and multifocal spikes on EEG during acute encephalitis have an increased risk of developing intractable epilepsy. To improve the outcome of postencephalitic epilepsy, intervention must occur earlier in the encephalitis stage.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17156696     DOI: 10.1177/7010.2006.00223

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  9 in total

1.  [Fulminant EBV meningoencephalitis : Good clinical outcome in a young, immunocompetent female].

Authors:  F Derler; S Seidel; D Bengel
Journal:  Nervenarzt       Date:  2017-10       Impact factor: 1.214

2.  Viral-like brain inflammation during development causes increased seizure susceptibility in adult rats.

Authors:  M A Galic; K Riazi; A K Henderson; S Tsutsui; Q J Pittman
Journal:  Neurobiol Dis       Date:  2009-08-04       Impact factor: 5.996

Review 3.  Seizures and epilepsy in herpes simplex virus encephalitis: current concepts and future directions of pathogenesis and management.

Authors:  Johann Sellner; Eugen Trinka
Journal:  J Neurol       Date:  2012-04-18       Impact factor: 4.849

4.  Seizures in 204 comatose children: incidence and outcome.

Authors:  Fenella J Kirkham; Angela M Wade; Fiona McElduff; Stewart G Boyd; Robert C Tasker; Melinda Edwards; Brian G R Neville; Norbert Peshu; Charles R J C Newton
Journal:  Intensive Care Med       Date:  2012-04-11       Impact factor: 17.440

5.  Postencephalitic epilepsy in dogs with meningoencephalitis of unknown origin: Clinical features, risk factors, and long-term outcome.

Authors:  Adriana Kaczmarska; Roberto José-López; Michał Czopowicz; Kali Lazzerini; Guillaume Leblond; Catherine Stalin; Rodrigo Gutierrez-Quintana
Journal:  J Vet Intern Med       Date:  2020-01-28       Impact factor: 3.333

6.  Startle Seizures and Diffuse Leukoencephalopathy After Resolution of Herpes Simplex Virus 1 Encephalitis in a Child.

Authors:  Andy Cheuk-Him Ng; Janani Kassiri; Helly R Goez; Francois Morneau-Jacob; Janette Mailo
Journal:  Child Neurol Open       Date:  2022-03-24

Review 7.  Antiepileptic drugs for the primary and secondary prevention of seizures in viral encephalitis.

Authors:  Sanjay Pandey; Chaturbhuj Rathore; Benedict D Michael
Journal:  Cochrane Database Syst Rev       Date:  2016-05-22

Review 8.  Epilepsy surgery: eligibility criteria and presurgical evaluation.

Authors:  Philippe Ryvlin; Sylvain Rheims
Journal:  Dialogues Clin Neurosci       Date:  2008       Impact factor: 5.986

9.  Prognostic Value of Initial Standard EEG and MRI in Patients with Herpes Simplex Encephalitis.

Authors:  Young Soo Kim; Keun Hwa Jung; Soon Tae Lee; Bong Su Kang; Jung Sook Yeom; Jangsup Moon; Jung Won Shin; Sang Kun Lee; Kon Chu
Journal:  J Clin Neurol       Date:  2016-01-28       Impact factor: 3.077

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.